# Merck Sharp & Dohme LLC clinical trials: 2,167 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,167 trials with Merck Sharp & Dohme LLC as lead sponsor, 132 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Merck Sharp & Dohme LLC: 2,167 rows for $101.67, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,167
- Recruiting or not yet: 132
- Read on: November 19, 2026

## Trials

The 25 newest of 2,167, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939399 | A Study of V951A in Healthy Participants (V951A-001) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Healthy Volunteers | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939399) |
| November 6, 2026 | NCT07922174 | A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Healthy, Renal Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922174) |
| November 5, 2026 | NCT07919028 | A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919028) |
| November 5, 2026 | NCT07917754 | A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Merck Sharp & Dohme LLC | Phase 2/3 | Not yet recruiting | Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917754) |
| November 2, 2026 | NCT07908537 | A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Small Cell Lung Cancer | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908537) |
| November 2, 2026 | NCT07908524 | MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) | Merck Sharp & Dohme LLC | Phase 1/2 | Not yet recruiting | Metastatic Castration-resistant Prostate Cancer | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908524) |
| October 28, 2026 | NCT07899905 | A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022) | Merck Sharp & Dohme LLC | Phase 4 | Not yet recruiting | Hypertension, Pulmonary | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899905) |
| October 26, 2026 | NCT07895524 | A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) | Merck Sharp & Dohme LLC | Phase 2 | Not yet recruiting | Rheumatoid Arthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895524) |
| October 15, 2026 | NCT07876128 | A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) | Merck Sharp & Dohme LLC | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Malignant Neoplasm | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876128) |
| October 15, 2026 | NCT07874815 | Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 2,136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874815) |
| October 13, 2026 | NCT07870278 | A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Ovarian Neoplasms, Endometrial Neoplasms | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870278) |
| October 9, 2026 | NCT07867938 | A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Pulmonary Sarcoidosis | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867938) |
| October 7, 2026 | NCT07862621 | A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862621) |
| October 7, 2026 | NCT07862595 | A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Pain Management | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862595) |
| October 7, 2026 | NCT07862569 | DOR/ISL in Pediatric Participants With HIV-1, \<18 Years of Age and ≥ 35 kg | Merck Sharp & Dohme LLC | Phase 2 | Not yet recruiting | HIV-1, HIV Infection | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862569) |
| October 6, 2026 | NCT07861074 | A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Noninfectious Intermediate, Posterior, or Panuveitis | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861074) |
| October 2, 2026 | NCT07855510 | A Clinical Trial of V175 and V175A in Healthy Adults | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Lower Respiratory Tract Infection | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855510) |
| September 30, 2026 | NCT07850609 | A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at... | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | HIV | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850609) |
| September 30, 2026 | NCT07850310 | A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Psoriasis, Healthy | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850310) |
| September 24, 2026 | NCT07839585 | A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure... | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Pulmonary Hypertension | 352 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839585) |
| September 21, 2026 | NCT07829783 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Bladder Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829783) |
| September 16, 2026 | NCT07821944 | A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Hyperlipidemia, Hypercholesterolemia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821944) |
| September 3, 2026 | NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer... | Merck Sharp & Dohme LLC | Phase 4 | Not yet recruiting | Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801027) |
| August 31, 2026 | NCT07793942 | A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Malignant Neoplam, Advanced Solid Tumors | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793942) |
| August 25, 2026 | NCT07785843 | A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Papillomavirus Infections | 930 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785843) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 642 |
| Phase 1/2 | 69 |
| Phase 2 | 462 |
| Phase 2/3 | 30 |
| Phase 3 | 716 |
| Phase 4 | 94 |
| Not applicable | 22 |
| Observational | 131 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,598 |
| Terminated | 284 |
| Recruiting | 116 |
| Active not recruiting | 96 |
| Withdrawn | 48 |
| Not yet recruiting | 16 |
| No longer available | 3 |
| Unknown | 3 |
| Approved for marketing | 2 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 181 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 177 |
| Hepatitis C, Chronic | 107 |
| Hepatitis C | 91 |
| Carcinoma, Non-Small-Cell Lung | 81 |
| HIV Infections | 70 |
| Neoplasms | 69 |
| Pneumococcal Infections | 43 |
| Papillomavirus Infections | 38 |
| Breast Neoplasms | 37 |
| Acquired Immunodeficiency Syndrome | 36 |
| Melanoma | 35 |
| Alzheimer Disease | 31 |
| Arthritis, Rheumatoid | 29 |
| Uterine Cervical Neoplasms | 29 |
| Hypertension | 29 |
| Chickenpox | 27 |
| Vomiting | 27 |
| Hypercholesterolemia | 27 |
| Herpes Zoster | 26 |
| Mycoses | 26 |
| Carcinoma, Renal Cell | 25 |
| Colorectal Neoplasms | 24 |
| Dyslipidemias | 22 |
| Renal Insufficiency | 22 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Radiology practices in the United States](https://specstream.ai/data/businesses/radiology-practices/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
